Loading
Chemours Co Stock: price and insider trades · United States
7 insiders bought €424k of shares over the last 90 days, the latest by Dignam Denise, filed 13 Aug 2026.
Chemours Co: what insiders have been doing
Chemours Co, founded in 2015, is a Chemicals & Materials company based in Wilmington, United States. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 22 filings signed by 9 insiders.
The flow runs one way only: 7 insiders bought (7 purchases totalling €424k) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Cowan Alister filed the largest purchase, €176k, on 11 August 2026, which represents 0.0094% of the company's market value. On the buying side, the filings list 2 senior executives, 1 finance chief and 1 chief executive among the declarants.
In the case of 6 purchases, another manager of the company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 13 August 2026, 66 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 22 filings, this issuer sits above that mark. The full history, which starts in 2016, counts 12 purchases against 3 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 5.81 bn USD and net income at -386.0 m USD; the dividend was 0.51 USD per share.
Other companies in the same sector with recent insider buying flagged by our signals: Culp Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
214
Thresholds
n/a
Buy Volume
€1M
12 ops. · all time
Sell Volume
€145,472
3 ops. · all time
Who traded when
BuySaleDenise Dignam2 buys
Shane Hostetter2 buys
Alister Cowan1 buy
Alvenia Scarborough1 sale
Calderon Gerardo Familiar1 buy
Damian Gumpel1 buy
+3 other insiders
Since the insiders bought
- -18.5%Entry US$15.85 · Close 15 Oct 2026 US$12.91
- -18.5%Entry US$15.85 · Close 15 Oct 2026 US$12.91
- -15.3%Entry US$15.24 · Close 15 Oct 2026 US$12.91
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Chemours Co Hold (neutral), based on 10 analysts. Average price target: US$16.90.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,972 of 24,166 companies
21.2
score / 100
Value30
Quality13
FCF yld2.7%
Earn yld-20%
EV/EBITDA19.0x
ROE·
Gross mgn16%
Net mgn-6.6%
Debt/EBITDA13.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$12.91
Analyst consensus
10 analystsHold
US$14.00Target US$16.90(+31%)US$24.00
Income statement
RevenueUS$5.8B
Gross profitUS$902M16% margin
EBITDAUS$332M6% margin
Net income-US$386M-5.2% margin
Valuation
PER (forward)6.9x
P/Book12.5x
Beta1.40
Balance sheet & cash
Market capUS$1.9B
Total debtUS$4.4B
Free Cash FlowUS$51M
Debt / Equity2034%
Profitability & ownership
ROE-319.4%
ROA1.4%
% insiders0.4%
% institutions91.2%
Last declaration on 13 August 2026
Declarations214 total
3,378 shares@ US$14.950.0023% mcap6.2% of flowCommon StockSEC:0001193125-26-349607:0
Canonical exit: 9 Nov 2026 (T+90)
1,935 shares@ US$15.530.0014% mcap16.4% of flowCommon StockSEC:0001193125-26-349656:0
Canonical exit: 10 Nov 2026 (T+90)
2,426 shares@ US$15.240.0017% mcap47.0% of flowCommon StockSEC:0001193125-26-349657:0
6,000 shares@ US$15.8250.0044% mcap100.0% of flowCommon StockSEC:0001193125-26-344632:0
Canonical exit: 5 Nov 2026 (T+90)
1,939.801 shares@ US$15.470.0014% mcap19.8% of flowCommon StockSEC:0001193125-26-344633:0
Canonical exit: 5 Nov 2026 (T+90)
1,934.231 shares@ US$15.510.0014% mcap100.0% of flowCommon StockSEC:0001193125-26-344634:0
Canonical exit: 5 Nov 2026 (T+90)
13,000 shares@ US$15.620.0094% mcap48.6% of flowCommon StockSEC:0001193125-26-344635:0
Canonical exit: 5 Nov 2026 (T+90)
3,087 shares@ US$15.110.0022% mcap19.3% of flowCommon StockSEC:0001193125-26-342338:0
3,350 shares@ US$14.940.0023% mcap20.7% of flowCommon StockSEC:0001193125-26-342481:0
Canonical exit: 4 Nov 2026 (T+90)
943 shares@ US$16.610.0007% mcap8.6% of flowCommon StockSEC:0001193125-26-332804:0
477 shares@ US$16.610.0004% mcap1.0% of flowCommon StockSEC:0001193125-26-332806:0
663 shares@ US$16.610.0005% mcap7.3% of flowCommon StockSEC:0001193125-26-332807:0
391 shares@ US$16.610.0003% mcap3.3% of flowCommon StockSEC:0001193125-26-332805:0
2,789 shares@ US$18.2432.7% of flowCommon StockSEC:0001193125-26-089431:0
3,232 shares@ US$18.2423.9% of flowCommon StockSEC:0001193125-26-089423:0
3,359 shares@ US$18.2430.0% of flowCommon StockSEC:0001193125-26-089517:0
2,635 shares@ US$18.2425.6% of flowCommon StockSEC:0001193125-26-089513:0
699 shares@ US$18.2415.9% of flowCommon StockSEC:0001193125-26-089403:0
22,220 shares@ US$18.2448.7% of flowCommon StockSEC:0001193125-26-089511:0
25,013 shares0Common StockSEC:0001193125-26-089503:0
1,781 shares0Common StockSEC:0001193125-26-077678:0
2,261 shares0Common StockSEC:0001193125-26-077676:0
1,294 shares@ US$15.4010.7% of flowCommon StockSEC:0000950170-25-112928:0
2,374 shares@ US$12.4237.1% of flowCommon StockSEC:0001062993-25-014470:0
4,068 shares@ US$12.066.0% of flowCommon StockSEC:0001062993-25-014200:0
Canonical exit: 6 Nov 2025 (T+90)
25 of 214 declarations
About Chemours Co
Chemours Co (ticker: CC) is a U.S.-listed chemical company traded on the NYSE in the United States (United States). The business was formed in 2015 through the spin-off of DuPont’s performance chemicals operations and began life as an independent public company. Its headquarters are in Wilmington, Delaware, giving Chemours a long-standing base in a major U.S. industrial hub. Today, the company positions itself as a global provider of performance chemicals, supported by a portfolio of well-known brands and leading positions in several specialized markets. ([chemours.com](https://www.chemours.com/en/news-media-center/all-news/press-releases/2015/the-chemours-company-completes-spin-off-from-dupont-and-launches-as-an-independent-publicly-traded-c?utm_source=openai))
Chemours is organized around three core segments: Thermal & Specialized Solutions (TSS), Titanium Technologies (TT), and Advanced Performance Materials (APM). TSS includes refrigerants and thermal-management solutions under the Opteon™ brand, serving air conditioning, industrial refrigeration, data centers, and broader energy-transition applications. TT is centered on titanium dioxide, marketed primarily through Ti-Pure™, a key input for paints, coatings, plastics, and paper. APM covers high-performance materials, including legacy brands such as Teflon™, Viton™, and Nafion™, with end markets spanning automotive, electronics, industrial processing, medical devices, and energy. This portfolio gives Chemours a mix of cyclical industrial exposure and more defensive specialty-chemistry franchises. ([chemours.com](https://www.chemours.com/en/about-chemours))
Read moreShow less
From a competitive standpoint, Chemours is better viewed as a specialty-chemicals platform than a pure commodity producer. Its value proposition is built on application expertise, customer-led product development, and trusted brands with strong market recognition. The company emphasizes its global reach and broad manufacturing footprint, which supports supply reliability and customer proximity. In 2025, performance remained uneven: TSS continued to show strong momentum, supported by growing adoption of Opteon™, while TT and APM faced softer demand in several cyclically sensitive end markets. A notable commercial highlight was the August 2025 qualification of Chemours’ two-phase immersion cooling fluid Opteon™ by Samsung Electronics, underlining the relevance of its advanced cooling technologies. At the same time, second-quarter 2025 results reflected litigation-related charges tied to the settlement announced with the State of New Jersey, reinforcing that legal and environmental liabilities remain an important part of the investment case. ([chemours.com](https://www.chemours.com/en/about-chemours))
For investors, Chemours combines specialty-chemistry upside, product innovation, and exposure to regulatory-driven refrigerant replacement opportunities. The offset is a meaningful risk profile: earnings are sensitive to titanium dioxide pricing, industrial demand cycles, and ongoing litigation and environmental issues. ([investors.chemours.com](https://investors.chemours.com/news-releases/news-release-details/chemours-company-reports-fourth-quarter-and-full-year-2025/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
